Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.38 +0.00%

+$0.00 today

Market cap
$622.71M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 1.30M

Average 0.54M

BCAX Operating Cash Flow

Cash generated by the company's core business operations during the period.

Bicara Therapeutics Inc. Common StockNASDAQ: BCAX

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow grows in line with its trailing trend

Q1 FY2026 operating cash flow of $37.51M (cash outflow) rose 33.5% year over year, ahead of the +31.7% change in trailing-twelve-month operating cash flow. Sequentially, it rose 57.0% from the prior quarter. Over 3 fiscal years it compounded at +49.3% a year.

Context

  • Operating cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +33.5% holds above the trailing-twelve-month pace of +31.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$37.51M+57.0% QoQ
Last fiscal yearDec 2025
-$106.83M+42.9% YoY
LTMMar 2026
-$116.24M+31.7% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.5%——
1 year+42.9%——
3-year CAGR+49.3%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(106.83M) USD
Year-over-year change
-42.9%

Operating Cash Flow vs competitors

How BCAX compares with its peers on the latest reported figures

  • BCAX's LTM Mar 2026 operating cash flow of $116.24M is the 2nd largest of the 6 companies compared; the peer median is $69.96M.
  • Its year-over-year change of +31.7% is the 2nd highest of 6, against a peer median of +18.9%.
  • Over three fiscal years its annual growth of +49.3% compares with a peer median of +12.9%.
BCAX Competitors Peer median
Operating Cash Flow for BCAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$178.64M +18.9%+11.5%—
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026$116.24M +31.7%+49.3%—
CBIOCrescent Biopharma, Inc.LTM Mar 2026$75.36M -4529.6%+15.5%634.2%
MGNXMacroGenics, Inc.LTM Mar 2026$69.96M +0.5%-2.3%44.5%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$53.2M +20.4%+12.9%—
CNTXContext Therapeutics Inc.LTM Mar 2026$32.79M +115.4%+24.9%—
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding BCAX) $69.96M+18.9%+12.9%339.4%

Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(37.85M)(51.99M)(68M)(137.95M)
Depreciation & Amortization10K19K56K406K
Deferred Income Tax0000
Stock-Based Compensation810K1.9M7.4M15.01M
Change in Working Capital4.95M(9.62M)(14.13M)14.81M
Accounts Receivables0000
Inventory0000
Accounts Payables002.64M0
Other Working Capital4.95M(9.62M)(16.77M)14.81M
Other Non-Cash Items810K14.06M(77K)895K
Operating Cash Flow(32.08M)(45.63M)(74.75M)(106.83M)
Capital Expenditures(192K)(586K)(71K)(280K)
Acquisitions (Net)0000
Purchases of Investments000(318.17M)
Sales of Investments0000
Other Investing Activities0062K0
Investing Cash Flow(192K)(586K)(9K)(318.45M)
Debt Repayment0000
Common Stock Issued00332.43M32.26M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities160K149K1.6M0
Financing Cash Flow31.7M272.5M334.03M32.26M
Effect of Forex Changes0000
Net Change in Cash(573K)226.28M259.27M(393.03M)
Free Cash Flow(32.27M)(46.21M)(74.82M)(107.11M)

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Intrinsic Alpha fair value

Locked

Current Price

$9.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.